NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range$1.82▼$9.8052-Week Range N/AVolume331,400 shsAverage Volume497,010 shsMarket Capitalization$59.27 millionP/E RatioN/ADividend YieldN/APrice Target$11.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Actinium Pharmaceuticals alerts: Email Address Actinium Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside∞ Upside$11.43 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.47) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.40 out of 5 starsMedical Sector767th out of 933 stocksPharmaceutical Preparations Industry362nd out of 440 stocks 3.4 Analyst's Opinion Consensus RatingActinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ATNM. Previous Next 0.0 Dividend Strength Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATNM. Previous Next 2.8 News and Social Media Coverage News SentimentActinium Pharmaceuticals has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Actinium Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest32 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat Follows9 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.47) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsOur #1 Gold Trade for 2024Gold is up a whopping 23% this year... Our #1 Gold play for 2024...Click here for the ticker >>> About Actinium PharmaceuticalsActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Read More Ad Behind the MarketsOur #1 Gold Trade for 2024Gold is up a whopping 23% this year... Our #1 Gold play for 2024...Click here for the ticker >>> ATNM Stock News HeadlinesSeptember 1 at 3:09 AM | americanbankingnews.comActinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.43 Consensus Price Target from BrokeragesAugust 29, 2024 | americanbankingnews.comStockNews.com Upgrades Actinium Pharmaceuticals (NYSE:ATNM) to HoldSeptember 3, 2024 | Behind the Markets (Ad)Our #1 Gold Trade for 2024Gold is up a whopping 23% this year... Our #1 Gold play for 2024...August 27, 2024 | americanbankingnews.comActinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.comAugust 26, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNMAugust 24, 2024 | stockhouse.comThe Schall Law Firm Is Investigating Actinium Pharmaceuticals Inc For Securities Fraud And Investors Are Encouraged To ParticipateAugust 21, 2024 | barrons.comActinium Pharmaceuticals Inc.August 20, 2024 | globenewswire.comActinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsSeptember 3, 2024 | Behind the Markets (Ad)Our #1 Gold Trade for 2024Gold is up a whopping 23% this year... Our #1 Gold play for 2024...August 20, 2024 | bizjournals.comCoya Therapeutics promotes recent C-suite hire to CEOAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNMAugust 15, 2024 | ca.finance.yahoo.comActinium Pharmaceuticals Inc (7AY1.DU)August 15, 2024 | ca.finance.yahoo.comATNM Aug 2024 10.000 callAugust 14, 2024 | 9to5mac.comHere’s what developers can do with the new NFC API for iPhone in iOS 18.1August 14, 2024 | globenewswire.comActinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNMAugust 8, 2024 | globenewswire.comActinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 8, 2024 | prnewswire.comATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmSee More Headlines Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ATNM CUSIPN/A CIK1388320 WebN/A Phone(646) 677-3870FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$11.43 High Stock Price Target$25.00 Low Stock Price Target$2.00 Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,820,000.00 Net MarginsN/A Pretax Margin-52,620.99% Return on Equity-101.69% Return on Assets-48.91% Debt Debt-to-Equity RatioN/A Current Ratio8.95 Quick Ratio8.95 Sales & Book Value Annual Sales$81,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / BookN/AMiscellaneous Outstanding Shares29,783,000Free Float28,592,000Market Cap$59.27 million OptionableOptionable Beta0.20 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key CompetitorsProcaps GroupNASDAQ:PROCGenfitNASDAQ:GNFTEliem TherapeuticsNASDAQ:ELYMPrelude TherapeuticsNASDAQ:PRLDTenaya TherapeuticsNASDAQ:TNYAView All CompetitorsInstitutional OwnershipThe Manufacturers Life Insurance Company Bought 12,488 shares on 8/15/2024Ownership: 0.042%Marshall Wace LLPBought 103,557 shares on 8/14/2024Ownership: 0.860%Squarepoint Ops LLCBought 48,096 shares on 8/14/2024Ownership: 0.161%Dimensional Fund Advisors LPSold 32,596 shares on 8/9/2024Ownership: 0.376%Renaissance Technologies LLCBought 19,200 shares on 8/9/2024Ownership: 0.064%View All Institutional Transactions ATNM Stock Analysis - Frequently Asked Questions How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) posted its quarterly earnings data on Monday, August, 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' top institutional investors include Marshall Wace LLP (0.86%), Dimensional Fund Advisors LP (0.38%), Bank of New York Mellon Corp (0.29%) and Squarepoint Ops LLC (0.16%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT) and Abiomed (ABMD). This page (NYSE:ATNM) was last updated on 9/3/2024 by MarketBeat.com Staff From Our PartnersFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredFREE Daily Profits Live Open HouseOver the past year, members of Millionaire trader Nate Bear's Daily Profits Live chatroom have had 62 opportun...Monument Traders Alliance | SponsoredAmazon coin set to soar 25X – starting September 23rdChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredKamala? Trump? _______? Think again. This play has delivered an annualized average gain of nearly 50% in just three months time… before every singl...The Freeport Society | SponsoredForget polls, focus on these 5 tickersWith all the geopolitical tensions in the world… all the inflation… all the expectations of a new round of Fed...StockEarnings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
